Publications by authors named "Matthew Hitron"

Claim this Profile
N
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Manish A Shah, Takayuki Yoshino, Niall C Tebbutt, Axel Grothey, Josep Tabernero, Matthew Hitron

Clin Colorectal Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center.
Henry Hiep Vo, Carrie Cartwright, I-Wen Song, Daniel D Karp, Graciela M Nogueras Gonzalez, Matthew Hitron

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Xiaoshu Dai, Michael D Karol, Matthew Hitron, Marjie L Hard, Matthew T Goulet

Clin Pharmacol Drug Dev· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass balance and pharmacokinetics of an oral dose of C-napabucasin in healthy adult male subjects.
Xiaoshu Dai, Michael D Karol, Matthew Hitron, Marjie L Hard, John Evan Blanchard

Pharmacol Res Perspect· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
Derek J Jonker, Louise Nott, Takayuki Yoshino, Sharlene Gill, Jeremy Shapiro, Matthew Hitron

Lancet Gastroenterol Hepatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis